Type 2 diabetes mellitus in midlife estimated from the Cambridge Risk Score and body mass index

Archives of Internal Medicine

Volumn 166, Issue 6, 2006, Pages 682-688

  Thomas, Claudia ^a   Hyppönen, Elina ^a   Power, Chris ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C;

ACCURACY; ADULT; ARTICLE; BODY MASS; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETIC OBESITY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

ADULT; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; GREAT BRITAIN; HEALTH SURVEYS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OBESITY; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 33645473408     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.166.6.682     Document Type: Article

References (34)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
2. Department of Health. National Service Framework for Diabetes: Standards. Published 2001. Available at: http://www.dh.gov.uk/assetRoot/04/05/89/38/ 04058938.pdf. Accessed June 22, 2005.
3. Harris MI, Eastman RC. Early detection of undiagnosed non-insulin-dependent diabetes mellitus. JAMA. 1996;276:1261-1262.
4. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care. 1992;15:815-819.
5. Wareham NJ, Griffin SJ. Should we screen for type 2 diabetes? evaluation against National Screening Committee criteria. BMJ. 2001;322:986-988.
6. Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ. Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. Diabetes Metab Res Rev. 2000;16:164-171.
7. Park PJ, Griffin SJ, Sargeant L, Wareham NJ. The performance of a risk score in predicting undiagnosed hyperglycemia. Diabetes Care. 2002;25:984-988.
8. 1c measurements: a consensus statement. Diabet Med. 2000;17:5-6.
9. Khaw K-T, Wareham NJ, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ. 2001;322:15-18.
10. Khaw K-T, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European Prospective Investigation into Cancer in Norfolk. Ann Intern Med. 2004;141:413-420.
11. Spijkerman A, Griffin S, Dekker J, Nijpels G, Wareham NJ. What is the risk of mortality for people who are screen positive in a diabetes screening programme but who do not have diabetes on biochemical testing? diabetes programmes from a public health perspective. J Med Screen. 2002;9:187-190.
12. Goyder E, Irwig L. Screening for diabetes: what are we really doing? BMJ. 1998;317:1644-1646.
13. Spijkerman AMW, Yuyun AF, Griffin SJ, Dekker JM, Nijpels G, Wareham NJ. The performance of a risk score as a screening test for undiagnosed hyperglycemia in ethnic minority groups. Diabetes Care. 2004;27:116-122.
14. Butler NR, Bonham DG. Perinatal Mortality. Edinburgh, Scotland: E&S Livingstone; 1963.
15. Ferri E. Life at 33: The Fifth Follow-up of the National Child Development Study. London, England: National Children's Bureau; 1993.
16. Hyppönen E, Power C, Davey-Smith G. Prenatal growth, BMI, and risk of type 2 diabetes by early midlife. Diabetes Care. 2003;26:2512-2517.
17. Hyppönen E, Davey-Smith G, Shepherd P, Power C. An intergenerational and lifecourse study of health and mortality risk in parents of the 1958 Birth Cohort, I: methods and tracing. Public Health. 2005;119:599-607.
18. Gibb I, Parnham A, Fonfréde M, Lecock F. Multicenter evaluation of Tosoh glycohemoglobin analyzer. Clin Chem. 1999;45:1833-1841.
19. 1c) testing. Diabetes Care. 2000;23:265-266.
20. Peters AL, Davidson MB, Schriger DL, Hasselblad V. A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels: Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. JAMA. 1996;276:1246-1252.
21. Davidson MB, Schriger DL, Peters AL, Lorber BL. Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. JAMA. 1999;281:1203-1210.
22. 1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: the Early Diabetes Intervention Program (EDIP). Diabetes Care. 2001;24:465-471.
23. 1c) in screening for undiagnosed diabetes in the US population. Diabetes Care. 2000;23:187-191.
24. Kirkwood BR, Sterne JAC. Medical Statistics. 2nd ed. Malden, Mass: Blackwell Publishers; 2003.
25. McCance DR, Hanson RL, Charles MA, et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ. 1994;308:1323-1328.
26. 1c for cost-effective screening. Diabetes Care. 2003;26:485-490.
27. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
28. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837-853.
29. Barr RG, Nathan DM, Meigs JB, Singer DE. Tests of glycemia for the diagnosis of type 2 diabetes mellitus. Ann Intern Med. 2002;137:263-272.
30. Edelman D, Edwards LJ, Olsen MK, et al. Screening for diabetes in an outpatient clinic population. J Gen Intern Med. 2002;17:23-28.
31. 1c in predicting diabetes risk. J Gen Intern Med. 2004;19:1175-1180.
32. Rathmann W, Martin S, Haastert B, et al. Performance of screening questionnaires and risk scores for undiagnosed diabetes. Arch Intern Med. 2005;165:436-441.
33. Brindle P, Emberson J, Lampe F, et al. Predictive accuracy of the Framingham Coronary Risk Score in British men: prospective cohort study. BMJ. 2003;327:1267-1270.
34. Thomsen TF, McGee D, Davidsen M, Jørgensen T. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol. 2002;31:817-822.